Evidence map›Paper›PMID 27534651›Full record

ReviewJournal of physiology and biochemistry2016

Angiotensin 2 type 1 receptor blockade different affects postishemic kidney injury in normotensive and hypertensive rats.

Zoran Miloradović, Milan Ivanov, Đurđica Jovović, Danijela Karanović, Una Jovana Vajić, Jasmina Marković-Lipkovski, Nevena Mihailović-Stanojević, Jelica Grujić Milanović

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of physiology and biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zoran MiloradovićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia. zokim@imi.bg.ac.rs.
Milan IvanovInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
Đurđica JovovićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
Danijela KaranovićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
Una Jovana VajićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
Jasmina Marković-LipkovskiInstitute of Pathology, Medical School University of Belgrade, Belgrade, Serbia.
Nevena Mihailović-StanojevićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
Jelica Grujić MilanovićInstitute for Medical Research University of Belgrade, Dr Subotića 4, PO Box 102, Belgrade, 11129, Serbia.
University of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies demonstrated that angiotensin 2 type 1 receptor (AT1R) blockade accelerates renal recovery in post-ischaemic kidney but there are many controversies related to its net effect on kidney structure and function. During the past years, our research group was trying to define the pathophysiological significance of the renin-angiotensin system on post-ischemic acute renal failure (ARF) development in normotensive Wistar as well as hypertensive rats (SHR). This review mostly summarizes our experience in that field. Our previous studies in normotensive rats revealed that AT1R blockade, except slightly renal vascular resistance improvement, had no other obvious beneficial effects, and therefore implies angiotensin 2 (Ang-2) overexpression as non-dominant on kidney reperfusion injuries development. Similarly it was observed in Wistar rats with induced mild (L-NAME, 3 mg/kg b.w.) nitric oxide (NO) deficiency. Expectably, in strong induced (L-NAME, 10 mg/kg b.w.) NO deficiency associated with ARF, massive tubular injuries indicate harmful effects of AT1R blockade, implying strongly disturbed glomerular filtration and suggesting special precaution related to AT1R blockers usage. Opposite to previous, by our opinion, AT1R antagonism promises new advance in treatment of essentially hypertensive subjects who develop ARF. Increased glomerular filtration, diminished oxidative stress, and most importantly improved tubular structure in postishemic SHR treated with AT1R blocker losartan, implicate Ang-2 over production as potently agent in the kidney ischemic injury, partly trough generation of reactive oxygen species. These data contribute understanding the pathogenesis of this devastating illness in hypertensive surroundings.

Indexed as

Acute Kidney InjuryAngiotensin II Type 1 Receptor BlockersAnimalsGene Expression RegulationGlomerular Filtration RateHypertensionKidneyLosartanNitric OxideRatsRats, Inbred SHRRats, WistarReactive Oxygen SpeciesReceptor, Angiotensin, Type 1Renal ArteryRenin-Angiotensin SystemAngiotensin II Type 1 Receptor BlockersLosartanNitric OxideReactive Oxygen SpeciesReceptor, Angiotensin, Type 1ExperimentalHypertensionLosartanNormotensionPostishemic kidney injury

Identifiers

PMID27534651
OpenAlexW2511316631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.